Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TGN-S11 + pembrolizumab
- Development stage
- Unknown
- Lead developer
- Toragen
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
TGN-S11 + pembrolizumab is an investigational combination therapy consisting of TGN-S11, a small molecule inhibitor of the human papillomavirus (HPV) E5 oncogene protein, and pembrolizumab (Keytruda), a monoclonal antibody PD-1 checkpoint inhibitor. TGN-S11 targets and inhibits the E5 oncogene, designed for selectivity against HPV-induced cancers, reducing both tumor size and circulating HPV DNA. Pembrolizumab blocks PD-1, restoring T-cell mediated immune responses against cancer cells. This combination is being assessed for synergistic anti-cancer effects in relapsed, resistant, or metastatic HPV-associated cancers[1][2][3][5][7].
- Other names
- TGN S11TGNS11TGNS-11TGNS 11Keytruda
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)HPV E5 (Human papillomavirus E5 protein)
Beyond the preview
Go deeper on TGN-S11 + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TGN-S11 + pembrolizumab.